Projected Earnings Date: 0000-02-29    (Delayed quote data   2026-02-10)
Last
 83.30
Change
 ⇓ -3.19   (-3.69%)
Volume
  138,812
Open
 86.94
High
 86.94
Low
 82.08
8EMA (Daily)
 82.21
40EMA (Daily)
 77.76
50EMA (Daily)
 76.41
STO (Daily)
 73.575
MACD Hist (Daily)
 1.022
8EMA (Weekly)
 78.715
40EMA (Weekly)
 54.60
50EMA (Weekly)
 49.69
STO (Weekly)
 60.849
MACD Hist (Weekly)
 -2.071
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2026 OptionChance.com